This is a preview of subscription content, log in via an institution to check access.
References
Lucas BA, Waid TH, Thompson JS, et al. Comparison of T10B9.1A-31 and OKT3 in treating acute renal allograft rejection. Trans Proc 1993 Feb; 25 Pt 1: 54–5
Waid TH, Lucas BA, Thompson JS, et al. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Transplantation 1997 Jul 27; 64: 274–81
Thompson JS, Brown SA, Barve S. Mechanism of immunosuppression by the murine IgM anti-T cell monoclonal antibody (mAb) T10B9.1A-31 (T10B9). J Cell Biochem 1995; Suppl. 21A: 179
Thompson JS, Brown SA, Barve S. T10B9.1A-31: a study of biofunctions important in the induction of tolerance. International Congress on New Immunosuppressive Drugs; 1995 Aug 27: 40
Brown SA, Lucas BA, Waid TH, et al. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant 1996 Dec; 10 Pt 2: 607–13
Henslee-Downey PJ, Parrish RS, Macdonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation 1996 Mar 15; 61: 738–45
Waid TH, Thompson JS, McKeown JW, et al. Induction immunotherapy in heart transplantation with T10B9.1A-31: a phase I study. J Heart Lung Transplant 1997 Sep; 16: 913–16
Waid TH, Sekela ME, Thompson JS, et al. Induction therapy with T10B9.1A31 is equivalent to OKT3 in cardiac allograft recipients. J Heart Lung Transplant 1995 Jan–Feb; 14 Pt 2: 50
Rights and permissions
About this article
Cite this article
MEDI 500. Drugs R&D 1, 92–94 (1999). https://doi.org/10.2165/00126839-199901010-00030
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901010-00030